Home >
Dr. Kapil Juvale

Dr. Kapil Juvale

Assistant Professor

Qualification              : M. Pharm., Ph.D.

Specialization            : Pharmaceutical Chemistry

E mail                         : kapil.juvale@nmims.edu

Phone                         : 022-42332000 (Extn-  2028)

Experience                 : 10.8 Year (Research: 2 years 6 months, Academics: 8 years 2 months)

Dr. Kapil has more than 10 years of research experience. He has obtained PhD in Pharmaceutical (medicinal) Chemistry from the University of Bonn, Germany in 2013. While pursuing his PhD he also worked as a research and teaching assistant from Oct. 2009-Feb. 2013. After completion of his PhD, he continued working in the same lab at the University of Bonn as a postdoctoral researcher. After returning to India, from Aug. 2014-July-2016 he worked as a postdoctoral fellow at the Indian Institute of Technology Gandhinagar. At the SPP School of Pharmacy & Technology Management, he is working as an Assistant Professor of Pharmaceutical Chemistry.

Interest areas:

  • Design and synthesis of small molecule modulators as anticancer agents
  • Development of small molecule inhibitors of Monocarboxylate transporters (MCT1 and MCT4) and ABC transporters involved in MDR in cancer
  • Study of bacterial proteins as potential antibacterial targets
  • Biochemical evaluation of small molecules


  • Publications – 27 (International- 27, National- 0)
  • Patents- 1 Granted, 2 Published
  • Presentations- 15 (International- 9, National- 6)
  • Research Grants: 08 (05 Completed, 03 Ongoing)

O Government funded projects: 01

  • Completed: Study of monocarboxylate transporters as potential targets to exploit hypoxia in cancer: design, synthesis and evaluation of MCT1 and MCT4 inhibitors.
    Funding agency: DST-SERB, Total Outlay: ₹ 47,82,604/-

O University Seed Grant: 01

  • Ongoing: Development of small molecule inhibitors of bacterial IMP dehydrogenase as potential therapeutics for infectious diseases. Total Outlay: ₹ 1,00,000/-

O Industry Projects: 05

  • Completed: Lead Optimisation Consortium India project involving development of potential drug candidates for Leishmaniasis sponsored by Drugs for Neglected Disease initiative(DNDi), Geneva, Switzerland. Total Outlay: ₹ 15,12,500/-
  • Completed: Collaborative research work with Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland for Lead Optimisation Consortium India (LOCI) project (Part I). Total Outlay: ₹ 14,96,000/-
  • Completed: Collaborative research work with Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland for Lead Optimisation Consortium India (LOCI) project (Part II). Total Outlay: ₹ 14,96,000/-
  • Ongoing: Completed: Collaborative research work with Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland for Lead Optimisation Consortium India (LOCI) project (Part III). Total Outlay: ₹ 14,96,000/-
  • Ongoing: MoU with Drugs for Neglected Diseases initiative (DNDi) for Open synthesis Network (OSN) involving multiple international Universities for Open-Source Drug Discovery. Total Fund Received: ₹ 1,05,604/-

Conferences/Workshops/Seminars attended- 34

Academic activities

He has guided 12 M. Pharm. students for their research projects and is currently guiding 02 M. Pharm. Students.

Currently, four candidates are registered for PhD under his supervision.


  • Teaching excellence award from SVKM’s NMIMS (2022).
  • Teaching excellence award from SVKM’s NMIMS (2019).
  • Indian National Science Academy (INSA) Visiting Scientist Programme 2018-19 Award (2019).
  • Postdoctoral fellowship from IIT Gandhinagar, India (2014-2016).
  • Full fellowship (€ 850) to attend ‘4th FEBS special meeting, ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Diseases’, Innsbruck, Austria. (2012).
  • Travel grant to attend ‘4th SFB-symposium, Transmembrane transporters in health and disease’, Vienna, Austria. (2011).
  • German academic exchange service (DAAD) fellowship for PhD at the University of Bonn, Germany (2009-2013).
  • Fellowship for Master of Pharmacy from AICTE, India (2005-2007).

Professional Memberships

  • Association of Pharmaceutical Teachers of India (APTI) – Life Membership (MA/LM-893)
  • Registered Pharmacist at Maharashtra State Pharmacy Council.

Recent Publications

  • Puri,S.; Stefan, K.; Khan, SL.; Pahnke, J.; Stefan, MS; Juvale, K.* Indole Derivatives as New Structural Class of Potent and Antiproliferative Inhibitors of Monocarboxylate Transporter 1 (MCT1; SLC16A1). J. Med. Chem. 2023, 66(1),657-676. [I.F. 8.039]
  • Puri, S.; Ahmad, I.; Patel, H.; Kumar, K.; Juvale, K.*, Evaluation of oxindole derivatives as a potential anticancer agent against breast carcinoma cells: In vitro, in silico, and molecular docking study. Toxicol. In Vitro. 2023, 86, 105517. [I.F. 3.685]
  • Puri, S.; Juvale, K.* Facile synthesis of new N1-alkylated 1H-indazole-3-carboxamide derivatives as potential anticancer agents: In vitro, ADMET prediction, and SAR studies. J. Mol. Struct. 2022, 1269, 133727. [I. F. 3.841]
  • Kalve, S.;  Hegde, N.;  Juvale, K.* Applications of Nanotechnology-Based Approaches to Overcome Multi-Drug Resistance in Cancer. Curr. Pharm. Des. 2022, 28(338), 3140-3157. [I.F. 3.116]
  • Puri, S.; Patil NS.; Juvale, K.* Investigation of some diethyl (4-(dimethylamino)-2,5-dihydro-2,5-dioxo-1-phenyl-1H-pyrrol-3-yl)(hydroxy)methylphosphonate derivatives for In silico pharmacokinetic profile and In vitro anticancer activity. Chem. Pap. 2022, 76, 6713–6721. [I.F. 2.097]
  • Puri, S.; Juvale, K.* Monocarboxylate transporter 1 and 4 inhibitors as potential therapeutics for treating solid tumours: A review with structure-activity relationship insights. Eur. J. Med. Chem. 2020, 199, 112393. [I.F. 5.572]
  • Hegde, N.; Juvale, K.*; Prabhakar, B. p-Toluenesulfonyl chloride catalysed facile synthesis of O-benzyl-L-amino acids and their in vitro evaluation. Int. J. Pept. Res. Ther. 2020, 26, 2129-2135. [I.F. 1.500]
  • Hegde, N.; Juvale, K.*; Prabhakar, B.*, Synthesis and in vitro evaluation of inherent properties of l-glutamic acid based dendritic lipopeptide oligomers, J. Pharm. Innov. 2022,  17, 228-236. [I. F. 2.722]
  • Hegde, N.; Juvale, K.*; Prabhakar, B. *, Formulation and optimization of gefitinib-loaded nanosuspension prepared using a newly developed dendritic lipopeptide oligomer material. Chem. Pap. 2021, 75, 2007-2022. [I.F. 2.097]
© Copyright 2024. Shri Vile Parle Kelavani Mandal (SVKM) All Rights Reserved.   Disclaimer  |  Privacy Policy